{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:16:18Z","timestamp":1772759778992,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.alit.2024.12.005","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:14:28Z","timestamp":1737533668000},"page":"435-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-5901","authenticated-orcid":false,"given":"Hiroyuki","family":"Nagase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Toma-Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Suzukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-5731","authenticated-orcid":false,"given":"Norihiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayoko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Terada-Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Komatsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Mizumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Kagoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-9815","authenticated-orcid":false,"given":"Yasunari","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Koya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9595-9657","authenticated-orcid":false,"given":"Masayuki","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Tagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-486X","authenticated-orcid":false,"given":"Akihiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Gon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2024.12.005_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2017.06.015","article-title":"Subphenotypes of type 2 severe asthma in adults","volume":"6","author":"Matsusaka","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2024.12.005_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.alit.2019.06.003","article-title":"Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.12.005_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.resinv.2024.02.007","article-title":"Changes in disease burden and treatment reality in patients with severe asthma","volume":"62","author":"Nagase","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.alit.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Flood-Page","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2024.12.005_bib8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2024.12.005_bib9","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"53","author":"Brown","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.12.005_bib10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2024.12.005_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.alit.2024.12.005_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs","volume":"13","author":"Llanos","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.alit.2024.12.005_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02345-2019","article-title":"Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme","volume":"55","author":"Taille","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.12.005_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis1","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.12.005_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u2018super-responder\u2019 to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.alit.2024.12.005_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2500\/aap.2020.41.200043","article-title":"Impact of mepolizumab on exacerbations in severe asthma: results from a U.S. insurance claims data base","volume":"41","author":"Ortega","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.alit.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/JAA.S319572","article-title":"Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months","volume":"14","author":"Kayser","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.alit.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.clinthera.2021.10.010","article-title":"Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis","volume":"43","author":"Silver","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.alit.2024.12.005_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2021.05.021","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities","volume":"127","author":"Casale","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib20","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1080\/02770903.2021.2008431","article-title":"Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review","volume":"59","author":"Israel","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.alit.2024.12.005_bib21","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2021.01.028","article-title":"Mepolizumab and oral corticosteroid stewardship: data from the Australian mepolizumab registry","volume":"9","author":"Thomas","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.12.005_bib22","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.alit.2024.12.005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106595","article-title":"Efficacy of mepolizumab in usual clinical practice and characteristics of responders","volume":"187","author":"Rodr\u00edguez-Garc\u00eda","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2024.12.005_bib24","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.5415\/apallergy.2021.11.e31","article-title":"Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma","volume":"11","author":"Kobayashi","year":"2021","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.alit.2024.12.005_bib25","doi-asserted-by":"crossref","first-page":"e12063","DOI":"10.1002\/clt2.12063","article-title":"Effectiveness of mepolizumab in severe asthma in Japan: a real-world study using claims data","volume":"11","author":"Nagase","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.alit.2024.12.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102130","article-title":"Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: a real-world database study in Japan","volume":"75","author":"Nagase","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.alit.2024.12.005_bib27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaip.2022.12.004","article-title":"Comorbidities modify the phenotype but not the treatment effectiveness to mepolizumab in severe eosinophilic asthma","volume":"11","author":"Kritikos","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.12.005_bib28","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.12.005_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/alr.23220","article-title":"Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: impact of comorbidity and sinus surgery","volume":"14","author":"Silver","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.alit.2024.12.005_bib30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000534902","article-title":"Effectiveness of mepolizumab in patients with severe eosinophilic asthma with\/without nasal polyposis: a real-life study","volume":"185","author":"Bravo-Guti\u00e9rrez","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib32","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.jaip.2023.07.024","article-title":"Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-A analysis","volume":"11","author":"Liu","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.12.005_bib33","first-page":"183","article-title":"Staging in rhinosinusitus","volume":"31","author":"Lund","year":"1993","journal-title":"Rhinology"},{"key":"10.1016\/j.alit.2024.12.005_bib34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.12.005_bib35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.7248\/jjrhi.52.143","volume":"52","author":"Haruna","year":"2013","journal-title":"Nihon Bika Gakkai Kaishi [Japanese J Rhinology]"},{"key":"10.1016\/j.alit.2024.12.005_bib36","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jaci.2006.09.005","article-title":"Rhinosinusitis: developing guidance for clinical trials","volume":"118","author":"Meltzer","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib37","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib38","series-title":"World Population Ageing 2019","year":"2019"},{"key":"10.1016\/j.alit.2024.12.005_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.anai.2023.01.003","article-title":"Characterization and cluster analyses of elderly asthma in comparison with nonelderly patients with asthma in Japan","volume":"130","author":"Suzukawa","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.alit.2023.02.006","article-title":"Executive summary: Japanese guidelines for adult asthma (JGL) 2021","volume":"72","author":"Niimi","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2024.12.005_bib41","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/biomedicines9111550","article-title":"Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma","volume":"9","author":"Maglio","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.alit.2024.12.005_bib42","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.alit.2024.12.005_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100462","article-title":"Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities","volume":"13","author":"Crimi","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.alit.2024.12.005_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/npjpcrm.2015.47","article-title":"Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study","volume":"25","author":"Kiljander","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.alit.2024.12.005_bib45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/15412555.2020.1817882","article-title":"Asthma COPD overlap PRO-CON debate. ACO: the mistaken term","volume":"17","author":"Papi","year":"2020","journal-title":"COPD"},{"key":"10.1016\/j.alit.2024.12.005_bib46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/15412555.2020.1817883","article-title":"Asthma-COPD overlap (ACO) PRO-CON debate. ACO: call me by my name","volume":"17","author":"Miravitlles","year":"2020","journal-title":"COPD"},{"key":"10.1016\/j.alit.2024.12.005_bib47","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2024.12.005_bib48","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.resinv.2021.02.009","article-title":"Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: a retrospective observational study","volume":"59","author":"Isoyama","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.alit.2024.12.005_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41533-020-00192-x","article-title":"Association of low-dosage systemic corticosteroid use with disease burden in asthma","volume":"30","author":"Matsunaga","year":"2020","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.alit.2024.12.005_bib50","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03054-2021","article-title":"Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality","volume":"60","author":"Skov","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2024.12.005_bib51","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/all.15627","article-title":"IL-5 receptor expression in lung fibroblasts: potential role in airway remodeling in asthma","volume":"78","author":"Bajbouj","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.12.005_bib52","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/all.14297","article-title":"Human airway epithelial cells express a functional IL-5 receptor","volume":"75","author":"Barretto","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2024.12.005_bib53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2024.12.005_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","article-title":"CT mucus score and (129)Xe MRI ventilation defects after 2.5 Years\u2019 anti-IL-5ralpha in eosinophilic asthma","volume":"164","author":"McIntosh","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.alit.2024.12.005_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1159\/000530392","article-title":"Effect of benralizumab on mucus plugs in severe eosinophilic asthma","volume":"184","author":"Sakai","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib56","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2169\/internalmedicine.3531-24","article-title":"Usefulness of mepolizumab for mucus plugs","volume":"63","author":"Hamakawa","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.alit.2024.12.005_bib57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaip.2022.09.008","article-title":"Clinical associations of mucus plugging in moderate to severe asthma","volume":"11","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2024.12.005_bib58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","article-title":"Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions","volume":"22","author":"Gibson","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2024.12.005_bib59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12890-019-0952-1","article-title":"Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis","volume":"19","author":"Numata","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.alit.2024.12.005_bib60","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2024.12.005_bib61","first-page":"576","article-title":"Mepolizumab in CRSwNP\/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia","volume":"62","author":"Fujieda","year":"2024","journal-title":"Rhinology"},{"key":"10.1016\/j.alit.2024.12.005_bib62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.23822\/EurAnnACI.1764-1489.94","article-title":"Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study","volume":"51","author":"Kurosawa","year":"2019","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2024.12.005_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S132389302400162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S132389302400162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:48:32Z","timestamp":1762368512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S132389302400162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S132389302400162X"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2024.12.005","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}